Welcome to a New Frontier in Understanding Alzheimer's

We are excited to introduce Alzheimer's LINX™, the new, ground-breaking test for detecting Alzheimer's-Associated Immune Reactivity.

Alzheimer's LINX™ is the result of years of research in environmental factors that are known to have an association with the development of Alzheimer's disease.
1 in 10 people age 65 and older has Alzheimer's disease.
Almost two-thirds of Americans with Alzheimer's are women.
According to the Alzheimer's association, 5.8 million Americans are living with Alzheimer's. By 2050, this number is projected to rise to nearly 14 million. Today, 1 in 3 seniors die with Alzheimer's or other dementia.

Window of Opportunity for Intervention

Pathological changes of Alzheimer's from normal, are classified into three major stages.
  • Preclinical
  • Mild Cognitive Impairment
  • Dementia

The Power of Predictive Antibodies

Identifying root causes in the earliest stages possible is crucial for developing interventional programs. Detect antibodies up to 20 years before symptoms actually appear!

Alzheimer's Disease and Environmental Factors

Alzheimer's LINX assess/measures immune reactivity to the following groups of key contributing factors:
BRAIN PROTEINS - brain proteins beyond amyloid-beta and tau
GROWTH FACTORS - factors involved in neuronal regeneration
ENTERIC NERVE, ENZYMES AND NEUROLOGICAL PEPTIDES - the communication pathway between the gut and the brain
PATHOGENS - known to cross-react with amyloid-beta
CHEMICALS - Biomarkers for a collection of chemicals/heavy metals discovered to have associations to Alzheimer's
FOOD THAT CROSS-REACT WITH AMYLOID-BETA - Eight out of 208 foods, newly discovered to have the potential association with Alzheimer's
BLOOD-BRAIN BARRIER AND NEUROFILAMENTS - Assesses the integrity of the blood-brain barrier
Cognitive Function Brain Health testing at Cyrex Labs.

Alzheimer's LINX™

Alzheimer's-Associated Immune Reactivity